US 12,478,605 B2
Biochanin a derivatives for treatment of BEST1-related retinopathies
Bernhard Weber, Obertraubling (DE); Andrea Milenkovic, Köfering (DE); Sabine Amslinger, Aschheim (DE); and Lisa Marie Dürr, Regensburg (DE)
Assigned to UNIVERSITÄT REGENSBURG, Regensburg (DE)
Appl. No. 17/995,093
Filed by Universität Regensburg, Regensburg (DE)
PCT Filed Mar. 30, 2021, PCT No. PCT/EP2021/058287
§ 371(c)(1), (2) Date Sep. 29, 2022,
PCT Pub. No. WO2021/198254, PCT Pub. Date Oct. 7, 2021.
Claims priority of application No. 20166646 (EP), filed on Mar. 30, 2020.
Prior Publication US 2023/0149344 A1, May 18, 2023
Int. Cl. A61K 31/352 (2006.01); A61P 27/02 (2006.01)
CPC A61K 31/352 (2013.01) [A61P 27/02 (2018.01)] 17 Claims
 
1. A method of treating a BEST1-related retinopathy, comprising administering to a subject in need a Biochanin A derivative or a salt thereof, wherein said Biochanin A derivative has the formula (II):

OG Complex Work Unit Chemistry
wherein
R1 is a proton, or OR1 is acetate, pentanoate, isopropylate, acrylate, methyl fumarate, butylcarbamate, isopropyl carbonate, isopropyloxycarbonylmethoxy, phosphate disodium salt or pivaloxymethyl, and
OR2 is acetate, pentanoate, isopropylate, acrylate, methyl fumarate, butylcarbamate, isopropyl carbonate, isopropyloxycarbonylmethoxy, phosphate disodium salt or pivaloxymethyl,
under the provision that when R1 is a proton, OR2 is acrylate, isopropyl carbonate, isopropyloxycarbonlymethoxy, phosphate disodium salt or pivaloxymethyl.